1. Editorial: first among Equals—not for either infliximab or adalimumab in Crohn's disease—yet. Issue 8 (25th March 2018) Authors: Lim, M. H.; Doecke, J. D.; Radford‐Smith, G. L. Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 8(2018) Page Start: 1225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort – authors' reply. Issue 6 (17th February 2017) Authors: Radford‐Smith, G. L.; Hartnell, F.; Doecke, J. D. Journal: Alimentary pharmacology & therapeutics Issue: Volume 45:Issue 6(2017) Page Start: 856 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort – authors' reply. Issue 6 (March 2017) Authors: Radford‐Smith, G. L.; Hartnell, F.; Doecke, J. D. Journal: Alimentary pharmacology & therapeutics Issue: Volume 45:Issue 6(2017) Page Start: 856 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. Issue 4 (19th December 2016) Authors: Doecke, J. D.; Hartnell, F.; Bampton, P.; Bell, S.; Mahy, G.; Grover, Z.; Lewindon, P.; Jones, L. V.; Sewell, K.; Krishnaprasad, K.; Prosser, R.; Marr, D.; Fischer, J.; R Thomas, G.; Tehan, J. V.; Ding, N. S.; Cooke, S. E.; Moss, K.; Sechi, A.; De Cruz, P. Journal: Alimentary pharmacology & therapeutics Issue: Volume 45:Issue 4(2017) Page Start: 542 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗